Renal cancer treatment has evolved significantly in recent years, offering patients more options than ever before. While surgery remains the cornerstone for early-stage disease, emerging therapies tested in clinical trials are expanding possibilities for those with advanced cancer, combining immune-boosting drugs with targeted molecules that attack cancer cells in specific ways.

How Doctors Approach Kidney Cancer Treatment Today

When someone is diagnosed with kidney cancer, also called renal cell carcinoma, the treatment plan is carefully designed based on several important factors. These include the stage of the cancer, which describes how far it has spread, the size and location of the tumor, and the patient’s overall health condition. The goal of treatment varies depending on the situation. For early-stage kidney cancer, doctors aim to remove the cancer completely and cure the disease. For more advanced cases where cancer has spread to other parts of the body, treatment focuses on controlling the cancer’s growth, managing symptoms, and helping patients maintain the best possible quality of life^[11][13].

Medical professionals follow established guidelines recommended by medical societies when planning treatment. These guidelines are based on years of research and clinical experience. However, medicine is constantly advancing, and alongside these standard approaches, researchers around the world are testing new therapies in clinical trials. These studies explore innovative ways to fight kidney cancer, offering hope for better outcomes and fewer side effects^[9][13].

Most people with kidney cancer are diagnosed when they are between 50 and 70 years old, though it can occur at any age. The disease affects men about twice as often as women. Fortunately, treatment options have improved dramatically over the past two decades, especially for people with advanced kidney cancer^[2][17].

Standard Treatment Approaches for Kidney Cancer

Surgery: The Primary Treatment

For most patients with kidney cancer that has not spread beyond the kidney or nearby tissue, surgery is the main treatment option. Surgery offers the best chance of curing the disease when the cancer is caught early. There are two main types of kidney cancer surgery, and the choice depends on the size and location of the tumor^[11][13].

A partial nephrectomy removes only the part of the kidney containing the tumor along with some surrounding tissue. This approach is now preferred for many patients with early-stage kidney cancer because it preserves kidney function. Studies have shown that long-term outcomes after partial nephrectomy are similar to those after complete kidney removal, but patients who keep more of their kidney tissue are less likely to develop chronic kidney disease later^[15][13].

A radical nephrectomy removes the entire kidney, often along with the adrenal gland above it, surrounding tissue, and nearby lymph nodes. This more extensive surgery may be necessary when the tumor is large or located in a position that makes partial removal impossible. Most people can live a normal, healthy life with one functioning kidney, though they need regular monitoring to ensure their remaining kidney stays healthy^[11][13].

Surgeons can perform kidney cancer surgery using two different approaches. In open surgery, the surgeon makes a single large incision in the abdomen or back. In laparoscopic surgery, also called minimally invasive surgery, the surgeon makes several small incisions and uses a tiny camera and specialized instruments to remove the kidney tissue. Some surgeons also use robotic assistance during laparoscopic procedures. The minimally invasive approach typically results in less pain, shorter hospital stays, and faster recovery^[13].

Other Local Treatment Methods

For patients who cannot undergo surgery because of other health problems or for small tumors, doctors may use ablation therapy. This approach destroys the tumor without removing it. The two main types are radiofrequency ablation, which uses heat to destroy cancer cells, and cryoablation, which freezes them. These treatments are typically performed through the skin using imaging guidance^[13].

Radiation therapy uses high-energy beams to kill cancer cells. While kidney cancer was traditionally thought to be resistant to radiation, newer precise techniques called stereotactic body radiotherapy (SBRT) are showing promise. Radiation is most often used to treat areas where kidney cancer has spread, such as the bones or brain, to relieve pain and other symptoms^[13][18].

Systemic Treatments for Advanced Kidney Cancer

When kidney cancer has spread beyond the kidney to other parts of the body, doctors use systemic treatments. These are medicines that travel through the bloodstream to reach cancer cells wherever they are in the body. Systemic treatments can be given as pills taken by mouth or as liquids delivered through a vein^[13].

There are two main categories of systemic treatments for kidney cancer: targeted therapies and immunotherapies. Targeted therapies work by blocking specific molecules that help cancer cells grow and spread. Many of these drugs interfere with the formation of new blood vessels that feed the tumor, a process controlled by a protein called vascular endothelial growth factor (VEGF). By cutting off the tumor’s blood supply, these medications can slow or stop cancer growth^[13][16].

Common targeted therapy drugs include sunitinib, cabozantinib, axitinib, pazopanib, and lenvatinib. Another type of targeted therapy blocks a protein called mTOR, which helps cancer cells grow and divide. Drugs in this category include everolimus and temsirolimus^[13].

Immunotherapies help the patient’s own immune system recognize and attack cancer cells. These drugs work by blocking proteins that prevent immune cells from doing their job. The most widely used immunotherapies for kidney cancer are called checkpoint inhibitors. They target proteins named PD-1, PD-L1, and CTLA-4. Examples include nivolumab, pembrolizumab, ipilimumab, and avelumab^[13][16].

Doctors often combine immunotherapy with targeted therapy because the two approaches work together effectively. For example, nivolumab combined with cabozantinib, or pembrolizumab combined with axitinib, are common combinations for first-line treatment of advanced kidney cancer. These combinations have been shown to help patients live longer and control their cancer better than older treatments^[13][16].

An older form of immunotherapy using cytokines such as interleukin-2 (IL-2) and interferon-alpha is sometimes still used, though less commonly now. These medications stimulate the immune system broadly and can cause significant side effects. They cause kidney cancers to shrink in approximately 10 to 20 percent of patients^[16].

Side Effects of Standard Treatments

All cancer treatments can cause side effects, though they vary from person to person. Surgical side effects depend on the extent of the operation but may include pain, infection, bleeding, and temporary changes in kidney function. Most people recover well from surgery^[11].

Targeted therapies can cause fatigue, diarrhea, high blood pressure, skin changes, and decreased appetite. Some drugs may affect thyroid function or cause problems with wound healing. Immunotherapies work by activating the immune system, which can sometimes cause inflammation in normal organs. Possible side effects include skin rashes, fatigue, diarrhea, and in rare cases, inflammation of the lungs, liver, intestines, or hormone-producing glands^[13][16].

It’s important to report any side effects to your medical team. Many side effects can be managed effectively with supportive medications or dose adjustments. Never change or stop your treatment without talking to your doctor first^[13].

Duration of Treatment

The duration of treatment depends on the stage of cancer and the type of therapy. Surgery is a one-time treatment, though recovery takes several weeks. For advanced kidney cancer, systemic treatments are often continued for as long as they are working and side effects remain manageable. Some patients may take these medications for months or even years. Regular imaging scans and blood tests help doctors monitor how well the treatment is working^[13][20].

Innovative Treatments Being Tested in Clinical Trials

Clinical trials are research studies that test new treatments or new combinations of existing treatments. These studies are essential for advancing kidney cancer care. Participating in a clinical trial may give patients access to promising new therapies before they become widely available. All clinical trials follow strict safety protocols and ethical guidelines^[9][13].

Understanding Clinical Trial Phases

Clinical trials for cancer treatments typically progress through several phases. Phase I trials test a new treatment in a small group of people to evaluate safety, determine safe dosage ranges, and identify side effects. Phase II trials give the treatment to a larger group to further assess safety and begin evaluating how well the treatment works. Phase III trials compare the new treatment to standard therapy in large groups of patients to confirm effectiveness, monitor side effects, and determine whether the new treatment is better than what is currently available^[13].

New Immunotherapy Combinations

Researchers are testing many new ways to combine immunotherapy drugs with each other or with targeted therapies. One promising approach being studied is combining pembrolizumab with belzutifan, a drug that works differently from standard targeted therapies. Belzutifan blocks a protein called HIF-2α that is often overactive in clear cell kidney cancer, the most common type. Early results from clinical trials suggest this combination shows anti-tumor activity^[16].

Another combination being investigated pairs belzutifan with lenvatinib, a targeted therapy that blocks blood vessel formation. This combination is being tested as a second-line treatment for patients whose cancer has progressed after initial therapy. Early clinical trial data indicate promise in controlling advanced kidney cancer^[16].

Adjuvant Therapy After Surgery

Adjuvant therapy refers to treatment given after surgery to reduce the risk of cancer coming back. Historically, adjuvant therapy was not commonly used for kidney cancer. However, newer immunotherapy drugs are being tested in this setting for patients at high risk of recurrence. For example, pembrolizumab and sunitinib are being studied as adjuvant treatments for patients with stage II and III kidney cancer after surgery. These studies aim to determine whether giving these medications after surgery can help patients stay cancer-free longer^[9][15].

Treatments for Less Common Kidney Cancer Types

Most clinical trials focus on clear cell renal cell carcinoma, which accounts for 70 to 80 percent of kidney cancers. However, researchers are also studying treatments specifically for non-clear cell kidney cancers, including papillary, chromophobe, and other rare subtypes. These cancers may respond differently to treatment than clear cell cancer. Studies are testing whether targeted therapies like bevacizumab combined with erlotinib can help patients with papillary kidney cancer^[8].

Biomarker Research

Scientists are working to identify biomarkers—measurable biological indicators—that can help predict which patients will respond best to specific treatments. One protein being studied is KIM-1, which may help doctors detect kidney cancer earlier and monitor treatment response. Research into biomarkers could lead to more personalized treatment approaches, where therapy is selected based on the specific characteristics of each patient’s cancer^[13].

Where Clinical Trials Are Conducted

Clinical trials for kidney cancer are conducted at major medical centers and cancer research institutions around the world, including in the United States, Europe, and many other countries. Some trials may be available at community hospitals that partner with larger research centers. Eligibility for clinical trials depends on many factors, including the stage and type of kidney cancer, previous treatments received, and overall health status^[9][13].

How Treatments in Trials Work

Many experimental treatments for kidney cancer work by targeting specific molecular pathways that cancer cells use to grow and survive. Some drugs block growth factor receptors on the surface of cancer cells. Others interfere with signals inside cells that tell them to divide. Still others help the immune system overcome the tricks that cancer cells use to hide from immune attack^[16].

For example, some investigational drugs target the MET pathway, which is often abnormally activated in papillary kidney cancer. Other experimental therapies aim to block HIF proteins, which help cancer cells adapt to low-oxygen conditions and are particularly important in clear cell kidney cancer. By attacking cancer cells through multiple different pathways simultaneously, combination therapies may be more effective than single drugs^[5][16].

Observation and Active Surveillance

Not all kidney cancers require immediate treatment. For small kidney tumors, especially in older patients or those with other serious health conditions, doctors may recommend active surveillance. This approach involves regular imaging tests to monitor the tumor over time without immediately treating it. If the tumor begins to grow or change, treatment can then be started. Studies have shown that many small kidney tumors grow very slowly, and some may never cause problems. Active surveillance allows patients to avoid treatment side effects while still being carefully monitored^[13].

Supportive and Palliative Care

Supportive care, also called palliative care, focuses on relieving symptoms and improving quality of life for people with kidney cancer. This type of care can be provided at any stage of treatment, not just at the end of life. Supportive care teams include doctors, nurses, social workers, nutritionists, and other specialists who help manage symptoms like pain, fatigue, nausea, and anxiety^[13][26].

Pain management is an important component of supportive care. Doctors can prescribe medications to control pain and may also recommend complementary approaches such as massage, meditation, or acupuncture. Other supportive services might include counseling for emotional distress, nutritional guidance, physical therapy to maintain strength and mobility, and help with practical issues like transportation to medical appointments^[24][27].

Most Common Treatment Methods

• Surgery
  • Partial nephrectomy removes only the tumor and surrounding tissue, preserving kidney function
  • Radical nephrectomy removes the entire kidney, adrenal gland, and nearby lymph nodes
  • Can be performed as open surgery or minimally invasive laparoscopic surgery
  • Robotic-assisted surgery is also available at some centers
• Targeted Therapy
  • Drugs like sunitinib, cabozantinib, axitinib, pazopanib, and lenvatinib block VEGF pathways to stop tumor blood vessel growth
  • mTOR inhibitors such as everolimus and temsirolimus block proteins that help cancer cells grow
  • Belzutifan blocks HIF-2α protein in clear cell kidney cancer
  • Typically taken as oral pills
• Immunotherapy
  • Checkpoint inhibitors including nivolumab, pembrolizumab, ipilimumab, and avelumab help the immune system attack cancer
  • Often combined with targeted therapy for better results
  • Cytokines like interleukin-2 and interferon-alpha stimulate the immune system broadly
  • Usually given through intravenous infusion
• Ablation Therapy
  • Radiofrequency ablation uses heat to destroy tumor tissue
  • Cryoablation freezes cancer cells
  • Performed through the skin using imaging guidance
  • Used for small tumors or patients who cannot have surgery
• Radiation Therapy
  • Stereotactic body radiotherapy (SBRT) delivers precise radiation to tumors
  • Most commonly used to treat areas where cancer has spread, such as bones or brain
  • Helps relieve pain and other symptoms from metastatic disease